Toujeo^® (insulin glargine 300 Units/mL) Versus insulin glargine 100 units/mL in T1DM

Hypoglycaemia is the most frequent adverse reaction observed in clinical trials conducted with Toujeo^®.² Other common adverse effects are lipohypertrophy and injection site reactions.²

For further information on the safety profile of Toujeo^® please consult the Summary of Product Characteristics >

1. Danne T, Matsuhisa M et al. Lower risk of severe hypoglycaemia with insulin glargine 300 U/mL versus glargine 100 U/mL in participants with type 1 diabetes: a meta-analysis of 6-month phase 3 clinical trials. Diabetes Obes Metab 2020;22(10):1880-1885
2. Toujeo® Summary of Product Characteristics. Available at: www.medicines.ie (Accessed July 2024)
3. Danne T, Tamborlane W V et al. Efficacy and safety of insulin glargine 300 units/ml (gla-300) versus insulin glargine 100 units/ml (gla-100) in children and adolescents (6-17 years) with type 1 diabetes: results of the EDITION JUNIOR randomised controlled trial. Diabetes Care 2020;43(7):1512-1519
4. Home P D, Bergenstal R M et al. New insulin glargine 300 units/ml versus glargine 100 units/ml in people with type 1 diabetes: a randomised, phase 3a, open-label clinical trial (EDITION 4). Diabetes Care 2015;38(12):2217-2225
5. Matsuhisa M, Koyama M et al. New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese adults with type 1 diabetes using basal and mealtime insulin: glucose control and hypoglycaemia in a randomised controlled trial (EDITION JP 1). Diabetes Obes Metab 2016;18(4):375-383
6. Danne T, Matsuhisa M et al. Lower risk of severe hypoglycaemia with insulin glargine 300 U/mL versus glargine 100 U/mL in participants with type 1 diabetes: a meta-analysis of 6-month phase 3 clinical trials. Diabetes Obes Metab 2020;22(10):1880-1885 (suppl)

ARR: Absolute Risk Reduction

HR: Hazard Ratio

OR: Odds Ratio

RR: Relative Risk

T1D – Type-1 Diabetes

T2D – Type -2 Diabetes